Treatment of Coronavirus Disease 2019: Shooting in the Dark

The identification of effective interventions against the coronavirus disease 2019 (COVID-19) pandemic has become a health priority. The rational treatment of a disease is based on the knowledge of its pathophysiology, the identification of a therapeutic target and the confirmation of the efficacy a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Juan Tamargo
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2020
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/6e6ad1d8941043fb870687c8706a963a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6e6ad1d8941043fb870687c8706a963a
record_format	dspace
spelling	oai:doaj.org-article:6e6ad1d8941043fb870687c8706a963a2021-12-04T16:03:24ZTreatment of Coronavirus Disease 2019: Shooting in the Dark10.15420/ecr.2020.211758-37641758-3756https://doaj.org/article/6e6ad1d8941043fb870687c8706a963a2020-08-01T00:00:00Zhttps://www.ecrjournal.com/articles/treatment-of-coronavirus-disease-2019https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764The identification of effective interventions against the coronavirus disease 2019 (COVID-19) pandemic has become a health priority. The rational treatment of a disease is based on the knowledge of its pathophysiology, the identification of a therapeutic target and the confirmation of the efficacy and safety of the selected therapeutic intervention in randomised controlled trials. However, we are facing the COVID-19 pandemic without a clear understanding of the pathophysiology of the disease. As we are fighting against a viral infection, drugs previously developed or approved to treat other viral infections or that exhibit a broad-spectrum antiviral activity, anti-inflammatory drugs and drugs against cytokine storm are currently being tested. Unfortunately, the efficacy and safety of these medications remain uncertain, and some may increase the risk of cardiovascular complications in patients with COVID-19. Thus, at the present time, due to the lack of solid scientific data to support a therapeutic strategy, we truly are shooting in the dark with the treatment of COVID-19. We must wait for the results of ongoing randomised, controlled studies before the widespread adoption of these drugs. In the meantime, investigational anti-COVID-19 drugs should be used in hospitals or as part of clinical trials.Juan TamargoRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 15, Iss , Pp - (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Juan Tamargo Treatment of Coronavirus Disease 2019: Shooting in the Dark
description	The identification of effective interventions against the coronavirus disease 2019 (COVID-19) pandemic has become a health priority. The rational treatment of a disease is based on the knowledge of its pathophysiology, the identification of a therapeutic target and the confirmation of the efficacy and safety of the selected therapeutic intervention in randomised controlled trials. However, we are facing the COVID-19 pandemic without a clear understanding of the pathophysiology of the disease. As we are fighting against a viral infection, drugs previously developed or approved to treat other viral infections or that exhibit a broad-spectrum antiviral activity, anti-inflammatory drugs and drugs against cytokine storm are currently being tested. Unfortunately, the efficacy and safety of these medications remain uncertain, and some may increase the risk of cardiovascular complications in patients with COVID-19. Thus, at the present time, due to the lack of solid scientific data to support a therapeutic strategy, we truly are shooting in the dark with the treatment of COVID-19. We must wait for the results of ongoing randomised, controlled studies before the widespread adoption of these drugs. In the meantime, investigational anti-COVID-19 drugs should be used in hospitals or as part of clinical trials.
format	article
author	Juan Tamargo
author_facet	Juan Tamargo
author_sort	Juan Tamargo
title	Treatment of Coronavirus Disease 2019: Shooting in the Dark
title_short	Treatment of Coronavirus Disease 2019: Shooting in the Dark
title_full	Treatment of Coronavirus Disease 2019: Shooting in the Dark
title_fullStr	Treatment of Coronavirus Disease 2019: Shooting in the Dark
title_full_unstemmed	Treatment of Coronavirus Disease 2019: Shooting in the Dark
title_sort	treatment of coronavirus disease 2019: shooting in the dark
publisher	Radcliffe Medical Media
publishDate	2020
url	https://doaj.org/article/6e6ad1d8941043fb870687c8706a963a
work_keys_str_mv	AT juantamargo treatmentofcoronavirusdisease2019shootinginthedark
_version_	1718372742284181504

Treatment of Coronavirus Disease 2019: Shooting in the Dark

Ejemplares similares